# Organogenesis Holdings Inc.: financial statements, quarterly

ORGO · Nasdaq · CIK 1661181 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/orgo.md) · [Financials](/companies/orgo/financials.md) · [Filings](/companies/orgo/filings.md) · [Insiders](/companies/orgo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/orgo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [109](/filings/0000950170-24-125431.md) | [99.7 d](/filings/0001193125-26-076730.md) | [110](/filings/0000950170-25-066962.md) | [130](/filings/0000950170-25-105048.md) | [115](/filings/0001193125-25-269697.md) | [127 d](/filings/0001193125-26-076730.md) | [86.7](/filings/0001661181-26-000008.md) | [101](/filings/0001193125-26-338049.md) | [151](/filings/0001193125-25-269697.md) | [226 d](/filings/0001193125-26-076730.md) | [37.2](/filings/0001661181-26-000008.md) | [43.8](/filings/0001193125-26-338049.md) |
| Cost of revenue | $m | [25.8](/filings/0000950170-24-125431.md) | [27.8 d](/filings/0000950170-25-029137.md) | [28.7](/filings/0000950170-25-066962.md) | [29.2](/filings/0000950170-24-094009.md) | [26.8](/filings/0000950170-24-125431.md) | [31.1 d](/filings/0000950170-25-029137.md) | [23.7](/filings/0000950170-25-066962.md) | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [82.7](/filings/0000950170-24-125431.md) | [71.9 d](/filings/0000950170-25-029137.md) | [81.3](/filings/0000950170-25-066962.md) | [101](/filings/0000950170-24-094009.md) | [88.4](/filings/0000950170-24-125431.md) | [95.6 d](/filings/0000950170-25-029137.md) | [63.0](/filings/0000950170-25-066962.md) | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [10.5](/filings/0000950170-24-125431.md) | [11.8 d](/filings/0001193125-26-076730.md) | [12.8](/filings/0000950170-25-066962.md) | [15.6](/filings/0000950170-25-105048.md) | [10.3](/filings/0001193125-25-269697.md) | [11.5 d](/filings/0001193125-26-076730.md) | [10.6](/filings/0001661181-26-000008.md) | [10.4](/filings/0001193125-26-338049.md) | [13.2](/filings/0001193125-25-269697.md) | [10.3 d](/filings/0001193125-26-076730.md) | [15.2](/filings/0001661181-26-000008.md) | [18.3](/filings/0001193125-26-338049.md) |
| Selling, general and administrative | $m | [64.2](/filings/0000950170-24-125431.md) | [61.4 d](/filings/0001193125-26-076730.md) | [72.3](/filings/0000950170-25-066962.md) | [76.5](/filings/0000950170-25-105048.md) | [71.8](/filings/0001193125-25-269697.md) | [73.9 d](/filings/0001193125-26-076730.md) | [72.5](/filings/0001661181-26-000008.md) | [73.8](/filings/0001193125-26-338049.md) | [79.7](/filings/0001193125-25-269697.md) | [100 d](/filings/0001193125-26-076730.md) | [65.2](/filings/0001661181-26-000008.md) | [54.0](/filings/0001193125-26-338049.md) |
| Operating income | $m | [8.1](/filings/0000950170-24-125431.md) | [(1.3) d](/filings/0001193125-26-076730.md) | [(3.9)](/filings/0000950170-25-066962.md) | [(13.9)](/filings/0000950170-25-105048.md) | [6.2](/filings/0001193125-25-269697.md) | [10.2 d](/filings/0001193125-26-076730.md) | [(26.7)](/filings/0001661181-26-000008.md) | [(12.6)](/filings/0001193125-26-338049.md) | [20.7](/filings/0001193125-25-269697.md) | [63.3 d](/filings/0001193125-26-076730.md) | [(68.9)](/filings/0001661181-26-000008.md) | [(51.0)](/filings/0001193125-26-338049.md) |
| Interest expense | $m | [0.4](/filings/0000950170-23-062056.md) | [0.5 d](/filings/0000950170-24-023150.md) | [0.5](/filings/0000950170-24-057050.md) | [0.6](/filings/0000950170-24-094009.md) | [0.5](/filings/0001193125-25-269697.md) | [(0.1) d](/filings/0001193125-26-076730.md) | [(1.0)](/filings/0001661181-26-000008.md) | [(0.7)](/filings/0001193125-26-338049.md) | [(0.4)](/filings/0001193125-25-269697.md) | [(0.2) d](/filings/0001193125-26-076730.md) | [(0.4)](/filings/0001661181-26-000008.md) | [(0.1)](/filings/0001193125-26-338049.md) |
| Income tax | $m | [4.5](/filings/0000950170-24-125431.md) | [(1.2) d](/filings/0001193125-26-076730.md) | [(2.2)](/filings/0000950170-25-066962.md) | [2.5](/filings/0000950170-25-105048.md) | [(6.5)](/filings/0001193125-25-269697.md) | [2.6 d](/filings/0001193125-26-076730.md) | [(6.9)](/filings/0001661181-26-000008.md) | [(2.4)](/filings/0001193125-26-338049.md) | [(0.4)](/filings/0001193125-25-269697.md) | [19.7 d](/filings/0001193125-26-076730.md) | [(15.3)](/filings/0001661181-26-000008.md) | [45.4](/filings/0001193125-26-338049.md) |
| Net income | $m | [3.2](/filings/0000950170-24-125431.md) | [(0.6) d](/filings/0001193125-26-076730.md) | [(2.1)](/filings/0000950170-25-066962.md) | [(17.0)](/filings/0000950170-25-105048.md) | [12.3](/filings/0001193125-25-269697.md) | [7.7 d](/filings/0001193125-26-076730.md) | [(18.8)](/filings/0001661181-26-000008.md) | [(9.4)](/filings/0001193125-26-338049.md) | [21.6](/filings/0001193125-25-269697.md) | [43.7 d](/filings/0001193125-26-076730.md) | [(53.2)](/filings/0001661181-26-000008.md) | [(96.3)](/filings/0001193125-26-338049.md) |
| Diluted EPS | $ per share | [0.02](/filings/0000950170-24-125431.md) | not reported | [(0.02)](/filings/0000950170-25-066962.md) | [(0.13)](/filings/0000950170-25-105048.md) | [0.09](/filings/0001193125-25-269697.md) | not reported | [(0.17)](/filings/0001661181-26-000008.md) | [(0.10)](/filings/0001193125-26-338049.md) | [0.11](/filings/0001193125-25-269697.md) | not reported | [(0.44)](/filings/0001661181-26-000008.md) | [(0.77)](/filings/0001193125-26-338049.md) |
| Basic EPS | $ per share | [0.02](/filings/0000950170-24-125431.md) | not reported | [(0.02)](/filings/0000950170-25-066962.md) | [(0.13)](/filings/0000950170-25-105048.md) | [0.09](/filings/0001193125-25-269697.md) | not reported | [(0.17)](/filings/0001661181-26-000008.md) | [(0.10)](/filings/0001193125-26-338049.md) | [0.11](/filings/0001193125-25-269697.md) | not reported | [(0.44)](/filings/0001661181-26-000008.md) | [(0.77)](/filings/0001193125-26-338049.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [98.2](/filings/0000950170-23-062056.md) | [104](/filings/0000950170-25-029137.md) | [88.6](/filings/0000950170-24-057050.md) | [89.9](/filings/0000950170-24-094009.md) | [94.3](/filings/0000950170-24-125431.md) | [136](/filings/0001193125-26-076730.md) | [110](/filings/0000950170-25-066962.md) | [73.1](/filings/0000950170-25-105048.md) | [63.7](/filings/0001193125-25-269697.md) | [93.7](/filings/0001193125-26-338049.md) | [91.4](/filings/0001661181-26-000008.md) | [46.1](/filings/0001193125-26-338049.md) |
| Current assets | $m | [226](/filings/0000950170-23-062056.md) | [225](/filings/0000950170-25-029137.md) | [227](/filings/0000950170-24-057050.md) | [234](/filings/0000950170-24-094009.md) | [239](/filings/0000950170-24-125431.md) | [286](/filings/0001193125-26-076730.md) | [268](/filings/0000950170-25-066962.md) | [260](/filings/0000950170-25-105048.md) | [300](/filings/0001193125-25-269697.md) | [362](/filings/0001193125-26-338049.md) | [269](/filings/0001661181-26-000008.md) | [200](/filings/0001193125-26-338049.md) |
| Total assets | $m | [463](/filings/0000950170-23-062056.md) | [460](/filings/0000950170-25-029137.md) | [458](/filings/0000950170-24-057050.md) | [443](/filings/0000950170-24-094009.md) | [446](/filings/0000950170-24-125431.md) | [498](/filings/0001193125-26-076730.md) | [467](/filings/0000950170-25-066962.md) | [461](/filings/0000950170-25-105048.md) | [510](/filings/0001193125-25-269697.md) | [599](/filings/0001193125-26-338049.md) | [520](/filings/0001661181-26-000008.md) | [406](/filings/0001193125-26-338049.md) |
| Current liabilities | $m | [81.5](/filings/0000950170-23-062056.md) | [80.5](/filings/0000950170-25-029137.md) | [82.8](/filings/0000950170-24-057050.md) | [85.7](/filings/0000950170-24-094009.md) | [77.3](/filings/0000950170-24-125431.md) | [77.5](/filings/0001193125-26-076730.md) | [65.1](/filings/0000950170-25-066962.md) | [65.8](/filings/0000950170-25-105048.md) | [90.3](/filings/0001193125-25-269697.md) | [100](/filings/0001193125-26-338049.md) | [76.0](/filings/0001661181-26-000008.md) | [57.0](/filings/0001193125-26-338049.md) |
| Total liabilities | $m | [186](/filings/0000950170-23-062056.md) | [181](/filings/0000950170-25-029137.md) | [180](/filings/0000950170-24-057050.md) | [180](/filings/0000950170-24-094009.md) | [168](/filings/0000950170-24-125431.md) | [113](/filings/0001193125-26-076730.md) | [99.3](/filings/0000950170-25-066962.md) | [99.9](/filings/0000950170-25-105048.md) | [124](/filings/0001193125-25-269697.md) | [165](/filings/0001193125-26-338049.md) | [139](/filings/0001661181-26-000008.md) | [118](/filings/0001193125-26-338049.md) |
| Long-term debt | $m | [68.0](/filings/0000950170-23-062056.md) | [66.6](/filings/0000950170-24-023150.md) | [65.2](/filings/0000950170-24-057050.md) | [63.8](/filings/0000950170-24-094009.md) | [62.3](/filings/0000950170-24-125431.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [277](/filings/0000950170-24-125431.md) | [279](/filings/0001193125-26-076730.md) | [278](/filings/0001193125-25-269697.md) | [264](/filings/0001193125-25-269697.md) | [279](/filings/0001193125-25-269697.md) | [263](/filings/0001193125-26-338049.md) | [243](/filings/0001193125-26-338049.md) | [233](/filings/0001193125-26-338049.md) | [255](/filings/0001193125-25-269697.md) | [300](/filings/0001193125-26-338049.md) | [245](/filings/0001193125-26-338049.md) | [148](/filings/0001193125-26-338049.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [16.7 d](/filings/0000950170-24-125431.md) | [10.6 d](/filings/0001193125-26-076730.md) | [(10.2)](/filings/0000950170-25-066962.md) | [4.7 d](/filings/0000950170-25-105048.md) | [8.7 d](/filings/0001193125-25-269697.md) | [10.9 d](/filings/0001193125-26-076730.md) | [(19.9)](/filings/0001661181-26-000008.md) | [(32.9) d](/filings/0001193125-26-338049.md) | [3.1 d](/filings/0001193125-25-269697.md) | [39.4 d](/filings/0001193125-26-076730.md) | [21.1](/filings/0001661181-26-000008.md) | [(31.7) d](/filings/0001193125-26-338049.md) |
| Capital expenditure | $m | [6.0 d](/filings/0000950170-24-125431.md) | [3.3 d](/filings/0001193125-26-076730.md) | [2.2](/filings/0000950170-25-066962.md) | [1.9 d](/filings/0000950170-25-105048.md) | [2.6 d](/filings/0001193125-25-269697.md) | [3.4 d](/filings/0001193125-26-076730.md) | [3.6](/filings/0001661181-26-000008.md) | [3.6 d](/filings/0001193125-26-338049.md) | [2.2 d](/filings/0001193125-25-269697.md) | [4.7 d](/filings/0001193125-26-076730.md) | [3.1](/filings/0001661181-26-000008.md) | [1.1 d](/filings/0001193125-26-338049.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [132](/filings/0000950170-23-062056.md) | [131](/filings/0000950170-24-057050.md) | [133](/filings/0000950170-24-094009.md) | [133](/filings/0000950170-24-125431.md) | [132](/filings/0000950170-25-066962.md) | [133](/filings/0000950170-25-105048.md) | [134](/filings/0001193125-25-269697.md) | [126](/filings/0001661181-26-000008.md) | [127](/filings/0001193125-26-338049.md) | [131](/filings/0001193125-25-269697.md) | [128](/filings/0001661181-26-000008.md) | [129](/filings/0001193125-26-338049.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 128,674,548 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338049.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.